{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:01:14Z","timestamp":1792123274054,"version":"4.4.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00059-018-4690-6","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T03:39:44Z","timestamp":1520480384000},"page":"651-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["In HFREF patients, sacubitril\/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization","Niedriger dosiertes Sacubitril\/Valsartan bei HFrEF bedingt keine erh\u00f6hte Mortalit\u00e4t oder Hospitalisierung"],"prefix":"10.1007","volume":"44","author":[{"given":"R.","family":"De Vecchis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Di Biase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Noutsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"issue":"13","key":"4690_CR1","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"CW Yancy","year":"2016","unstructured":"Yancy CW, Jessup M, Bozkurt B et al (2016) 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practiceguidelines and the Heart Failure Society of America. J\u00a0Am Coll Cardiol 68(13):1476\u20131488","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"4690_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891\u2013975","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"4690_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"5","key":"4690_CR4","first-page":"102","volume":"34","author":"L Lullo Di","year":"2017","unstructured":"Di Lullo L, Ronco C, Bellasi A et al (2017) Neprilysin inhibition and chronic kidney disease. G\u00a0Ital Nefrol 34(5):102\u2013112 (Article in Italian)","journal-title":"G Ital Nefrol"},{"issue":"10","key":"4690_CR5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Packer M et al (2016) Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail 18(10):1228\u20131234","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"4690_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a\u00a0new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461\u2013470","journal-title":"Ann Intern Med"},{"key":"4690_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-017-4671-1","author":"R Vecchis De","year":"2018","unstructured":"De Vecchis R, Ariano C, Di Biase G, Noutsias M (2018) Sacubitril\/valsartan for heart failure with reduced left ventricular ejection fraction. A\u00a0retrospective cohort study. Herz. \n                    https:\/\/doi.org\/10.1007\/s00059-017-4671-1","journal-title":"Herz"},{"issue":"23","key":"4690_CR8","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N\u00a0Engl J Med 316(23):1429\u20131435","journal-title":"N Engl J Med"},{"issue":"14","key":"4690_CR9","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1517\/14740338.2015.1102225","volume":"12","author":"RG Kiel","year":"2015","unstructured":"Kiel RG, Deedwania P (2015) The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified? Expert Opin Drug Saf 12(14):1855\u20131863","journal-title":"Expert Opin Drug Saf"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-018-4690-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T17:00:56Z","timestamp":1572022856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-018-4690-6"}},"subtitle":["A\u00a0retrospective cohort study","Eine retrospektive Kohortenstudie"],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["4690"],"URL":"https:\/\/doi.org\/10.1007\/s00059-018-4690-6","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,8]]},"assertion":[{"value":"14 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"M.\u00a0Noutsias has received grants by the Deutsche Forschungsgemeinschaft (DFG) through the Sonderforschungsbereich Transregio\u00a019 \u201cInflammatory Cardiomyopathy\u201d (SFB TR19; TP B2), and by the University Hospital Giessen and Marburg Foundation Grant \u201cT cell functionality\u201d (UKGM 10\/2009). M.\u00a0Noutsias has been consultant to the Institute for Cardiac Diagnosis and Therapy, Berlin (06\/2004-06\/2008) and has received honoraria for presentations and\/or participated in advisory boards from AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius, Miltenyi Biotech, Novartis, Pfizer and Zoll. R.\u00a0De Vecchis, C.\u00a0Ariano and G.\u00a0Di Biase declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}